PMID- 22568905
OWN - NLM
STAT- MEDLINE
DCOM- 20120827
LR  - 20220309
IS  - 1557-7988 (Electronic)
IS  - 0076-6879 (Linking)
VI  - 509
DP  - 2012
TI  - Targeting nanoparticles to dendritic cells for immunotherapy.
PG  - 143-63
LID - 10.1016/B978-0-12-391858-1.00008-3 [doi]
AB  - Dendritic cells (DCs) are key players in the initiation of adaptive immune 
      responses and are currently exploited in immunotherapy for treatment of cancer 
      and infectious diseases. Development of targeted nanodelivery systems carrying 
      vaccine components, including antigens and adjuvants, to DCs in vivo represents a 
      promising strategy to enhance immune responses. Delivering particulate vaccines 
      specifically to DCs and preventing nonspecific uptake by other endocytotic cells 
      are challenging. Size represents a critical parameter determining whether 
      particulate vaccines can penetrate lymph nodes and reach resident DCs. Specific 
      delivery is further enhanced by actively targeting DC-specific receptors. This 
      chapter discusses the rationale for the use of particle-based vaccines and 
      provides an overview of antigen-delivery vehicles currently under investigation. 
      In addition, we discuss how vaccine delivery systems may be developed, focusing 
      on liposomes, PLGA polymers, and gold nanoparticles, to obtain safe and 
      efficacious vaccines.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - Cruz, Luis J
AU  - Cruz LJ
AD  - Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, 
      Radboud University Medical Centre, Nijmegen, The Netherlands.
FAU - Tacken, Paul J
AU  - Tacken PJ
FAU - Rueda, Felix
AU  - Rueda F
FAU - Domingo, Joan Carles
AU  - Domingo JC
FAU - Albericio, Fernando
AU  - Albericio F
FAU - Figdor, Carl G
AU  - Figdor CG
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Methods Enzymol
JT  - Methods in enzymology
JID - 0212271
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antibodies, Immobilized)
RN  - 0 (Antigens)
RN  - 0 (Immunoglobulin Fc Fragments)
RN  - 0 (Liposomes)
RN  - 0 (Nanocapsules)
RN  - 0 (Nanoconjugates)
RN  - 0 (Vaccines, Synthetic)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 7440-57-5 (Gold)
SB  - IM
MH  - Adjuvants, Immunologic/chemistry
MH  - Amino Acid Sequence
MH  - Animals
MH  - Antibodies, Immobilized/chemistry
MH  - Antigens/chemistry/immunology
MH  - Dendritic Cells/*immunology
MH  - Gold/chemistry
MH  - Humans
MH  - Immunoglobulin Fc Fragments/chemistry
MH  - Immunotherapy/*methods
MH  - Lactic Acid
MH  - Liposomes/chemistry
MH  - Molecular Sequence Data
MH  - Nanocapsules/*chemistry
MH  - Nanoconjugates/chemistry
MH  - Polyglycolic Acid
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
MH  - Vaccines, Synthetic/chemistry
EDAT- 2012/05/10 06:00
MHDA- 2012/08/28 06:00
CRDT- 2012/05/10 06:00
PHST- 2012/05/10 06:00 [entrez]
PHST- 2012/05/10 06:00 [pubmed]
PHST- 2012/08/28 06:00 [medline]
AID - B978-0-12-391858-1.00008-3 [pii]
AID - 10.1016/B978-0-12-391858-1.00008-3 [doi]
PST - ppublish
SO  - Methods Enzymol. 2012;509:143-63. doi: 10.1016/B978-0-12-391858-1.00008-3.